Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.84 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.79 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.75 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.67 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2455314 | 0.97 | KMT2A (0.84) | KMT2APLA2G4BNR1H4SMPD1PLA2G2A | |
| SCHEMBL8081150 | 0.95 | KMT2A (0.82) | KMT2APLA2G4BNR1H4SMPD1PLA2G2A | |
| SCHEMBL8082044 | 0.95 | KMT2A (0.82) | KMT2APLA2G4BNR1H4SMPD1PLA2G2A | |
| SCHEMBL8080220 | 0.95 | KMT2A (0.82) | KMT2APLA2G4BNR1H4SMPD1PLA2G2A | |
| SCHEMBL7822821 | 0.95 | KMT2A (0.82) | KMT2APLA2G4BNR1H4SMPD1PLA2G2A | |
| SCHEMBL7047692 | 0.95 | KMT2A (0.82) | KMT2APLA2G4BNR1H4SMPD1PLA2G2A | |
| SCHEMBL15766225 | 0.95 | KMT2A (0.82) | KMT2APLA2G4BNR1H4SMPD1PLA2G2A | |
| SCHEMBL8086388 | 0.95 | KMT2A (0.82) | KMT2APLA2G4BNR1H4SMPD1PLA2G2A | |
| SCHEMBL2887568 | 0.95 | KMT2A (0.82) | KMT2APLA2G4BNR1H4SMPD1PLA2G2A | |
| SCHEMBL4652291 | 0.95 | KMT2A (0.82) | KMT2APLA2G4BNR1H4SMPD1PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5817825-A | Process for the preparation of 1-hydroxy-2-pyridones | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-10-06 | — | — | US | claimed |
| CN-112812077-B | Benzamide compound, preparation method thereof, pharmaceutical composition and application | 中国科学院上海药物研究所 | 2023-08-22 | — | — | CN | disclosed |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2023-05-04 | — | — | US | disclosed |
| CN-112812077-A | Benzamide compound and preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2021-05-18 | — | — | CN | disclosed |
| CN-110785474-A | Flame retardant composition and flame-retardant resin composition containing same | 株式会社艾迪科 | 2020-02-11 | — | — | CN | disclosed |
| US-8486974-B2 | Efficient aspirin prodrugs | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) | 2013-07-16 | — | — | US | disclosed |
| US-8466199-B2 | Allyloxy and alkyloxy benzoic acid delivery agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466199-B2 | Allyloxy and alkyloxy benzoic acid delivery agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466199-B2 | Allyloxy and alkyloxy benzoic acid delivery agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| EP-0710650-A2 | Process for the preparation of 1-hydroxy-2-pyridones | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-05-08 | — | — | EP | disclosed |
| US-5514702-A | Arylamidoalkyl-N-hydroxyurea compounds having lipoxygenase inhibitory activity | ABBOTT LABORATORIES (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0401503-B1 | Solid non-hygroscopic trialkylamine oxides | ALBEMARLE CORP (US) | 1996-01-17 | — | — | EP | disclosed |
| US-5422360-A | Hydrazonoimidazolidin-4-one derivatives; treatment of diabetes and aging disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-06-06 | — | — | US | disclosed |
| EP-0595995-A4 | ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LAB (US) | 1994-08-24 | — | — | EP | disclosed |
| EP-0595995-A1 | ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY. | ABBOTT LAB (US) | 1994-05-11 | — | — | EP | disclosed |
| US-5214204-A | Inhibitors of biosynthesis of leukotrienes | ABBOTT LABORATORIES (US) | 1993-05-25 | — | — | US | disclosed |
| EP-0531812-A1 | Maillard reaction inhibitor, process for producing it, composition containing it and the use thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-17 | — | — | EP | disclosed |
| WO-1993002037-A1 | ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LABORATORIES (US) | 1993-02-04 | — | — | WO | disclosed |
| US-4342875-A | STABILIZERS FOR OLEFIN POLYMERS | CINCINNATI-MILACRON, INC. (US) | 1982-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | RXFP1, RXFP2, RXFP4 | KMT2A 2674/4885PLA2G4B 1155/4885NR1H4 331/4885 |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | KMT2A 3772/4885PLA2G4B 254/4885NR1H4 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.